Detalhe da pesquisa
1.
Alzheimer's disease marker phospho-tau181 is not elevated in the first year after moderate-to-severe TBI.
J Neurol Neurosurg Psychiatry
; 95(4): 356-359, 2024 Mar 13.
Artigo
Inglês
| MEDLINE | ID: mdl-37833041
2.
Feeding after spawning and energy balance at spawning are associated with repeat spawning interval in steelhead trout.
Gen Comp Endocrinol
; 332: 114181, 2023 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36455641
3.
Distinct patterns of neurodegeneration after TBI and in Alzheimer's disease.
Alzheimers Dement
; 19(7): 3065-3077, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-36696255
4.
Magnesium and calcium overaccumulate in the leaves of a schengen3 mutant of Brassica rapa.
Plant Physiol
; 186(3): 1616-1631, 2021 07 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33831190
5.
Sodium hyperaccumulators in the Caryophyllales are characterized by both abnormally large shoot sodium concentrations and [Na]shoot/[Na]root quotients greater than unity.
Ann Bot
; 129(1): 65-78, 2022 01 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34605859
6.
Detecting axonal injury in individual patients after traumatic brain injury.
Brain
; 144(1): 92-113, 2021 02 12.
Artigo
Inglês
| MEDLINE | ID: mdl-33257929
7.
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.
N Engl J Med
; 378(26): 2475-2485, 2018 06 28.
Artigo
Inglês
| MEDLINE | ID: mdl-29782224
8.
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
N Engl J Med
; 378(26): 2486-2496, 2018 06 28.
Artigo
Inglês
| MEDLINE | ID: mdl-29782217
9.
Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.
Gastroenterology
; 158(1): 111-122.e10, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31593702
10.
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases.
Clin Exp Allergy
; 51(7): 915-931, 2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-34037993
11.
Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma.
Ann Allergy Asthma Immunol
; 126(5): 584-592.e1, 2021 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33465455
12.
Diffuse axonal injury predicts neurodegeneration after moderate-severe traumatic brain injury.
Brain
; 143(12): 3685-3698, 2020 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33099608
13.
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Lancet
; 394(10209): 1638-1650, 2019 11 02.
Artigo
Inglês
| MEDLINE | ID: mdl-31543428
14.
Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis.
Allergy
; 75(1): 148-157, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31306495
15.
Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis.
Ann Allergy Asthma Immunol
; 125(5): 565-576.e1, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32474156
16.
Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.
J Am Acad Dermatol
; 82(6): 1328-1336, 2020 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-32135208
17.
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.
J Am Acad Dermatol
; 83(5): 1282-1293, 2020 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-32574587
18.
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
J Am Acad Dermatol
; 82(2): 377-388, 2020 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-31374300
19.
Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP.
Rhinology
; 58(1): 10-17, 2020 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31671432
20.
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.
J Allergy Clin Immunol
; 143(1): 155-172, 2019 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30194992